NewYork Presbyterian Lawrence Hospital

New York City, New York, United States

NewYork Presbyterian Lawrence Hospital

New York City, New York, United States
SEARCH FILTERS
Time filter
Source Type

Smyth L.M.,Sloan Kettering Cancer Center | Iyengar N.M.,Sloan Kettering Cancer Center | Chen M.F.,Sloan Kettering Cancer Center | Popper S.M.,Sloan Kettering Cancer Center | And 14 more authors.
Breast Cancer Research and Treatment | Year: 2016

We previously reported progression-free survival (PFS) results on a phase II trial of weekly paclitaxel, trastuzumab, and pertuzumab in patients with human epidermal growth factor receptor 2(HER2)–positive metastatic breast cancer (MBC) treated in the first- and second-line setting. Here, we report results for overall survival (OS) and updated PFS after an additional year of follow-up. Patients with HER2-positive MBC with 0–1 prior treatment were eligible. Treatment consisted of paclitaxel (80 mg/m2) weekly, and trastuzumab (loading dose 8 mg/kg → 6 mg/kg) and pertuzumab (loading dose 840 mg → 420 mg) every 3 weeks, all given intravenously. Primary endpoint was 6-month PFS. Secondary endpoints included median PFS, 6-month and median OS. Evaluable patients received at least one full dose of treatment. From January 2011 to December 2013, 69 patients were enrolled: 51 (74 %) and 18 (26 %) treated in first- and second-line metastatic settings, respectively. As of July 1, 2015, the median follow-up was 33 months (range 3–49 months; 67 patients were evaluable for efficacy). The median OS was 44 months (95 % CI 37.5–NR) overall and 44 months (95 % CI 38.3–NR) and 37.5 months (95 % CI 30.3–NR) for patients with 0 and 1 prior metastatic treatment, respectively; 6-month OS was 98 % (95 % CI 90-1). The 6-month PFS was 86 % (95 % CI 75–93) overall and 89 % (95 % CI 76–95) and 78 % (95 % CI 51–91) for patients with 0 and 1 prior therapy, respectively; and median PFS was 21.4 months (95 % CI 14.1–NR) overall and 25.7 months (95 % CI 14.1–NR) and 16.9 months (95 % CI 8.5–NR) for patients with 0–1 prior treatment, respectively. Treatment was well tolerated. Updated analysis demonstrates that weekly paclitaxel, when added to trastuzumab and pertuzumab, is associated with a favorable OS and PFS and offers an alternative to docetaxel-based therapy. http://www.ClinicalTrials.govNCT0127604 © 2016 Springer Science+Business Media New York


PubMed | Sloan Kettering Cancer Center, CLION and NewYork Presbyterian Lawrence Hospital
Type: Journal Article | Journal: Breast cancer research and treatment | Year: 2016

We previously reported progression-free survival (PFS) results on a phase II trial of weekly paclitaxel, trastuzumab, and pertuzumab in patients with human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer (MBC) treated in the first- and second-line setting. Here, we report results for overall survival (OS) and updated PFS after an additional year of follow-up. Patients with HER2-positive MBC with 0-1 prior treatment were eligible. Treatment consisted of paclitaxel (80mg/m(2)) weekly, and trastuzumab (loading dose 8mg/kg6mg/kg) and pertuzumab (loading dose 840mg420mg) every 3weeks, all given intravenously. Primary endpoint was 6-month PFS. Secondary endpoints included median PFS, 6-month and median OS. Evaluable patients received at least one full dose of treatment. From January 2011 to December 2013, 69 patients were enrolled: 51 (74%) and 18 (26%) treated in first- and second-line metastatic settings, respectively. As of July 1, 2015, the median follow-up was 33months (range 3-49months; 67 patients were evaluable for efficacy). The median OS was 44months (95% CI 37.5-NR) overall and 44months (95% CI 38.3-NR) and 37.5months (95% CI 30.3-NR) for patients with 0 and 1 prior metastatic treatment, respectively; 6-month OS was 98% (95% CI 90-1). The 6-month PFS was 86% (95% CI 75-93) overall and 89% (95% CI 76-95) and 78% (95% CI 51-91) for patients with 0 and 1 prior therapy, respectively; and median PFS was 21.4months (95% CI 14.1-NR) overall and 25.7months (95% CI 14.1-NR) and 16.9months (95% CI 8.5-NR) for patients with 0-1 prior treatment, respectively. Treatment was well tolerated. Updated analysis demonstrates that weekly paclitaxel, when added to trastuzumab and pertuzumab, is associated with a favorable OS and PFS and offers an alternative to docetaxel-based therapy. http://www.ClinicalTrials.gov NCT0127604.

Loading NewYork Presbyterian Lawrence Hospital collaborators
Loading NewYork Presbyterian Lawrence Hospital collaborators